WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 20/05/2024 am IST			5-day change	1st Jan Change
44.7 ^CNY	-0.45%		-0.33%	-38.57%

16/05	WuXi AppTec Denies Being a Security Threat to US	MT
16/05	HONG KONG SHARES OF WUXI APPTEC SET TO OPEN DOWN 2.1% AFTER US H…	RE

WuXi AppTec Co., Ltd. Provides Revenue Guidance for the First Quarter and Full Year of 2022

March 09, 2022 at 07:45 pm IST

WuXi AppTec Co., Ltd. provided revenue guidance for the first quarter and full year of 2022. For the first quarter, the company expected that its year-over-year revenue growth will reach 65% to 68%.

For the full year of 2022, the year-over-year revenue growth of the company is expected to reach 65% to 70%.

Latest news about WuXi AppTec Co., Ltd.

WuXi AppTec Denies Being a Security Threat to US	16/05	MT
HONG KONG SHARES OF WUXI APPTEC SET TO OPEN DOWN 2.1% AFTER US H…	16/05	RE
US House committee advances bill to restrict BGI, WuXi AppTec	15/05	RE
US HOUSE OVERSIGHT COMMITTEE VOTES TO ADVANCE LEGISLATION RESTRI…	15/05	RE
US House committee to vote on bill to restrict BGI, WuXi AppTec	15/05	RE
Chinese Stocks Muted as Investors Eye US Inflation Data, New Tariffs; Wuxi AppTec Rises Despite Biosecure Act Draft	14/05	MT
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms	14/05	MT
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling	13/05	DJ
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties	10/05	RE
Wuxi Apptec Co., Ltd. Proposes Final Cash Dividend Payment for the Financial Year Ended 31 December 2023	09/05	CI
Trade association survey shows 79% of US biotech companies contract with Chinese firms	09/05	RE
Beijing, Fed Churn Asian Stock Markets in Sparse Trading	03/05	MT
WuXi AppTec Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Full Year 2024	29/04	CI
Interest Rate Outlooks Quell Asian Stock Markets	17/04	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	12/04	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04	MT
Tranche Update on WuXi AppTec Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	02/04	CI
China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators	28/03	RE
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET	19/03	DJ
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET	19/03	DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	19/03	DJ
Nomura Adjusts Wuxi Apptec’s Price Target to 62.75 Yuan From 99.16 Yuan, Keeps at Buy	19/03	MT
Nomura Adjusts Wuxi Apptec’s Price Target to HK$54.56 From HK$86.23, Keeps at Buy	19/03	MT
Hong Kong Shares Slip Amid Downbeat Earnings, Cautious Trade	19/03	MT

Chart WuXi AppTec Co., Ltd.

Duration

Period

More charts

Company Profile

WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for WuXi AppTec Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.7 CNY

Average target price

68.82 CNY

Spread / Average Target

+53.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WUXI APPTEC CO., LTD.	-38.57%	17.71B
VERTEX PHARMACEUTICALS INCORPORATED	+9.70%	115B
REGENERON PHARMACEUTICALS, INC.	+11.59%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-13.11%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.10%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+6.84%	14.32B
SAREPTA THERAPEUTICS, INC.	+34.10%	12.42B
LEGEND BIOTECH CORPORATION	-24.05%	8.23B

Bio Therapeutic Drugs